Pipeline2019-03-04T16:14:25-04:00

Product Pipeline

EyePoint has developed five FDA-approved products utilizing our proprietary DurasertTM and VerisomeTM Technologies.

We are utilizing our Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions, and are available to collaborate on our VerisomeTM Technology.

Product/ProgramPhase
Dexycu (dexamethasone intraocular suspension) 9%Approved
Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mgApproved
Yutiq shorter duration treatmentPreclinical
Durasert TKI
Potential Indication: Wet AMD
Preclinical
Collaboration on glaucomaPreclinical
Verisome Technology - PGE
Potential Indication: glaucoma
Preclinical
Verisome Technology - NSAID
Potential Indication: cataract surgery inflammation
Preclinical
Dexycu (dexamethasone injectable suspension) 9%
Learn More at dexycu.com
click here for full Prescribing Information

Please complete the form below to receive information on the availability of Dexycu.

Dexycu (dexamethasone injectable suspension) 9%
Learn More at yutiq.com
click here for full Prescribing Information

Please complete the form below to receive information on the availability of Yutiq.

YutiqTM Shorter Duration for Posterior Uveitis

Potential Indication: posterior segment uveitis

EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.

DurasertTM Bioerodible TKI

Potential Indication: Wet AMD

EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs.